完整後設資料紀錄
DC 欄位語言
dc.contributor.authorChiang, Chih-Shengen_US
dc.contributor.authorHu, Shang-Hsiuen_US
dc.contributor.authorLiao, Bang-Jieen_US
dc.contributor.authorChang, Yuan-Chingen_US
dc.contributor.authorChen, San-Yuanen_US
dc.date.accessioned2014-12-08T15:33:56Z-
dc.date.available2014-12-08T15:33:56Z-
dc.date.issued2014-01-01en_US
dc.identifier.issn1549-9634en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.nano.2013.07.009en_US
dc.identifier.urihttp://hdl.handle.net/11536/23393-
dc.description.abstractTrastuzumab-conjugated pH-sensitive double emulsion nanocapsules (DENCs) stabilized by a single-component Poly (vinyl alcohol) (PVA) with magnetic nanoparticles can be fabricated through a two-step double emulsion process; these nanocapsules can be used to encapsulate hydrophilic doxorubicin (Dox) and hydrophobic paclitaxel (PTX) simultaneously. When PMA(SH) was attached to the shell of the DENCs, enhanced dual drug release of PTX/Dox was detected, specifically in intracellular acidic pH environments. The targeting ability of these Trastuzumab-conjugated DENCs was demonstrated with confocal images, which revealed a significantly elevated cellular uptake in HER-2 overexpressing SkBr3 cells. More importantly, an intravenous injection of this co-delivery system followed by magnetic targeting (MT) chemotherapy suppressed cancer growth in vivo more efficiently than the delivery of either PTX or Dox alone. The integration of the functionalities makes this combination therapy system a powerfully new tool for in vitro/in vivo cancer therapy, especially for in HER-2 positive cancers. From the Clinical Editor: Trastuzumab-conjugated pH-sensitive nanocapsules were used in this study for simultaneous targeted delivery of hydrophobic (PTX) and hydrophilic (Dox) anti-cancer agents to HER-2 positive cancer cells. Additional use of magnetic targeting demonstrated superior efficacy of this delivery system compared to PTX or Dox alone. (C) 2014 Elsevier Inc. All rights reserved.en_US
dc.language.isoen_USen_US
dc.subjectEmulsionen_US
dc.subjectpH sensitiveen_US
dc.subjectHER-2 positive breast canceren_US
dc.subjectTrastuzumaben_US
dc.subjectCo-deliveryen_US
dc.titleEnhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compoundsen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.nano.2013.07.009en_US
dc.identifier.journalNANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINEen_US
dc.citation.volume10en_US
dc.citation.issue1en_US
dc.citation.spage99en_US
dc.citation.epage107en_US
dc.contributor.department材料科學與工程學系zh_TW
dc.contributor.departmentDepartment of Materials Science and Engineeringen_US
dc.identifier.wosnumberWOS:000329103500011-
dc.citation.woscount3-
顯示於類別:期刊論文


文件中的檔案:

  1. 000329103500011.pdf

若為 zip 檔案,請下載檔案解壓縮後,用瀏覽器開啟資料夾中的 index.html 瀏覽全文。